Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that the U.S. Food and Drug Administration has accepted the New Drug Application for Maxigesic® IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain.
November 1, 2021
· 5 min read